Implementation strategies for passive respiratory syncytial virus immunisation

Sande, Charles J

doi:10.1016/s1473-3099(20)30717-9

Cited by 4 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite these limitations, our study is, to our knowledge, the first attempt to estimate the RSV hospitalization burden in children under the age of 5 years across the EU, and in EU countries for which no estimates have been produced so far. These estimates should help optimize public health responses (eg, the allocation of more resources to pediatric hospitals during the winter season) and support planning for future immunization programs [ 33 ]. Additionally, they could help gain a better understanding of the impact of RSV-associated hospitalizations on the increased risk of premature adult deaths from respiratory disease [ 34 ].…”

Section: Discussionmentioning

confidence: 99%

Burden of Respiratory Syncytial Virus in the European Union: estimation of RSV-associated hospitalizations in children under 5 years

Del Riccio,

Spreeuwenberg,

Osei-Yeboah

et al. 2023

The Journal of Infectious Diseases

View full text Add to dashboard Cite

Background No overall estimate of RSV-associated hospitalisations in children under 5 years has been published for the European Union (EU). We aimed to estimate the RSV hospitalisation burden in children under 5 years in EU countries and Norway, by age group. Methods We collated national RSV-associated hospitalisation estimates calculated using linear regression models via the RESCEU project for Denmark, England, Finland, Norway, the Netherlands and Scotland during 2006-2018. Additional estimates were obtained from a systematic review. Using the multiple imputation and nearest neighbour matching methods, we estimated overall RSV-associated hospitalisations and rates in the EU. Results Additional estimates for only two countries (France and Spain) were found in the literature. In the EU, an average of 245,244 (95%CI 224,688-265,799) yearly hospital admissions with a respiratory infection per year were associated with RSV in children under the age of 5, with most cases occurring among children aged less than 1 year (75%). Infants aged less than 2 months represented the most affected group (71.6 per 1,000 children; 66.6-76.6). Conclusion Our findings will help support decisions regarding prevention efforts and represent an important benchmark to understand changes in the RSV burden following the introduction of RSV immunisation programs in Europe.

show abstract

Section: Discussionmentioning

confidence: 99%

Burden of Respiratory Syncytial Virus in the European Union: estimation of RSV-associated hospitalizations in children under 5 years

Del Riccio,

Spreeuwenberg,

Osei-Yeboah

et al. 2023

The Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…Despite these limitations, our study is, to our knowledge, the first attempt to estimate the RSV hospitalisation burden in children under the age of 5 years across Europe, and in EU countries for which no estimates have been produced so far. These estimates should help optimize public health responses (e.g., the allocation of more resources to pediatric hospitals during the winter season) and support planning for future immunisation programs [37]. Moreover, they represent a benchmark to understand to understand changes in the RSV burden after the COVID-19 pandemic and in the future following the introduction of RSV immunisation programs in Europe.…”

Section: Whilst It Is Important To Properly Understand the Real Burde...mentioning

confidence: 99%

Defining the Burden of Disease of RSV in Europe: estimates of RSV-associated hospitalisations in children under 5 years of age. A systematic review and modelling study

Riccio

Spreeuwenberg

Osei‐Yeboah

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Respiratory syncytial virus (RSV) infections cause an estimated 22-50 million episodes of acute lower respiratory infections (ALRI) every year in children younger than 5 years. To date, no overall estimate of RSV-associated hospitalisations in children under 5 years has been published for the European Union (EU). Through statistical modelling, we estimated the RSV hospitalisation burden in children under 5 years of age in EU countries and Norway, by age group and country. Methods: We collated national RSV-associated hospitalisation estimates calculated using linear regression models in children under 5 years via the RESCEU project for Denmark, England, Finland, Norway, the Netherlands and Scotland during 2006-2018. A systematic literature review was conducted to collect additional estimates. Using the multiple imputation and nearest neighbor matching extrapolation methods, we estimated RSV-associated hospitalisation rates in all EU countries. Results: Additional estimates for Spain and France were found in the literature and added to the analysis. We estimated that an average of 245,244 (95%CI 224,688-265,799) hospital admissions with a respiratory infection per year were associated with RSV in children under the age of 5, with most cases occurring among children aged less than 1 year (75%). Infants aged less than 2 months represented the most affected group (71.6 per 1,000 children; 95%CI: 66.6-76.6). The hospitalisation rates varied widely across countries: for example, estimated rates in the 0-2 months age group ranged from 47.4 (37.5-57.3) per 1,000 in the Netherlands to 98.3 (88.5-108.1) per 1,000 in France. Conclusion: To our knowledge, this is the first attempt to estimate the overall RSV hospitalisation burden in children under the age of 5 years in the EU. Our findings will help support decisions regarding prevention efforts, and they will also represent an important benchmark to understand changes in the RSV burden following the introduction of RSV immunisation programs in Europe.

show abstract

“…Despite the considerable burden associated with RSV disease, and RSV being considered a global health priority, currently, there is no preventative strategy for all infants and treatment is generally limited to symptomatic relief ( 21 ). RSV is also one of the few major causes of severe pediatric infection with no available vaccine ( 22 ). Palivizumab, a monoclonal antibody (mAb) licensed for >20 years, is the only prophylaxis available against RSV.…”

Section: Introductionmentioning

confidence: 99%

RSV Prevention in All Infants: Which Is the Most Preferable Strategy?

et al. 2022

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) causes a spectrum of respiratory illnesses in infants and young children that may lead to hospitalizations and a substantial number of outpatient visits, which result in a huge economic and healthcare burden. Most hospitalizations happen in otherwise healthy infants, highlighting the need to protect all infants against RSV. Moreover, there is evidence on the association between early-life RSV respiratory illness and recurrent wheezing/asthma-like symptoms As such, RSV is considered a global health priority. However, despite this, the only prevention strategy currently available is palivizumab, a monoclonal antibody (mAb) indicated in a subset of preterm infants or those with comorbidities, hence leaving the majority of the infant population unprotected against this virus. Therefore, development of prevention strategies against RSV for all infants entering their first RSV season constitutes a large unmet medical need. The aim of this review is to explore different immunization approaches to protect all infants against RSV. Prevention strategies include maternal immunization, immunization of infants with vaccines, immunization of infants with licensed mAbs (palivizumab), and immunization of infants with long-acting mAbs (e.g., nirsevimab, MK-1654). Of these, palivizumab use is restricted to a small population of infants and does not offer a solution for all-infant protection, whereas vaccine development in infants has encountered various challenges, including the immaturity of the infant immune system, highlighting that future pediatric vaccines will most likely be used in older infants (>6 months of age) and children. Consequently, maternal immunization and immunization of infants with long-acting mAbs represent the two feasible strategies for protection of all infants against RSV. Here, we present considerations regarding these two strategies covering key areas which include mechanism of action, “consistency” of protection, RSV variability, duration of protection, flexibility and optimal timing of immunization, benefit for the mother, programmatic implementation, and acceptance of each strategy by key stakeholders. We conclude that, based on current data, immunization of infants with long-acting mAbs might represent the most effective approach for protecting all infants entering their first RSV season.

show abstract

Implementation strategies for passive respiratory syncytial virus immunisation

Cited by 4 publications

References 10 publications

Burden of Respiratory Syncytial Virus in the European Union: estimation of RSV-associated hospitalizations in children under 5 years

Burden of Respiratory Syncytial Virus in the European Union: estimation of RSV-associated hospitalizations in children under 5 years

Defining the Burden of Disease of RSV in Europe: estimates of RSV-associated hospitalisations in children under 5 years of age. A systematic review and modelling study

RSV Prevention in All Infants: Which Is the Most Preferable Strategy?

Contact Info

Product

Resources

About